Myriad Genetics, Inc. (NASDAQ:MYGN) has been assigned an average recommendation of “Hold” from the thirteen analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $24.75.

MYGN has been the topic of several analyst reports. Leerink Swann reissued a “market perform” rating and set a $31.00 price target on shares of Myriad Genetics in a report on Monday. Stephens restated an “overweight” rating and issued a $40.00 price target (up previously from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Cowen and Company restated a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a research report on Sunday, September 17th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $23.00 price objective (up previously from $21.00) on shares of Myriad Genetics in a research note on Thursday, August 10th. Finally, Deutsche Bank AG raised Myriad Genetics from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $27.86 to $15.00 in a research note on Friday, August 18th.

Shares of Myriad Genetics (MYGN) opened at 37.13 on Wednesday. Myriad Genetics has a one year low of $15.15 and a one year high of $37.14. The stock has a 50 day moving average of $31.93 and a 200-day moving average of $24.64. The stock has a market capitalization of $2.54 billion, a P/E ratio of 116.39 and a beta of 0.28.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The firm had revenue of $200.50 million during the quarter, compared to analyst estimates of $193.71 million. During the same period in the prior year, the business posted $0.36 EPS. Myriad Genetics’s revenue was up 7.5% on a year-over-year basis. Equities analysts forecast that Myriad Genetics will post $1.02 earnings per share for the current year.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total value of $909,000.00. Following the completion of the transaction, the director now directly owns 52,524 shares in the company, valued at approximately $1,591,477.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.20% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in MYGN. SG Americas Securities LLC purchased a new position in shares of Myriad Genetics during the second quarter valued at about $101,000. Riverhead Capital Management LLC increased its holdings in shares of Myriad Genetics by 80.9% in the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock worth $107,000 after purchasing an additional 1,861 shares during the last quarter. Fiduciary Trust Co. bought a new stake in shares of Myriad Genetics in the second quarter worth about $113,000. Ameritas Investment Partners Inc. bought a new stake in shares of Myriad Genetics in the first quarter worth about $112,000. Finally, Ronald Blue & Co. LLC bought a new stake in shares of Myriad Genetics in the second quarter worth about $208,000.

ILLEGAL ACTIVITY WARNING: “Myriad Genetics, Inc. (MYGN) Receives Average Recommendation of “Hold” from Brokerages” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/04/myriad-genetics-inc-mygn-receives-average-recommendation-of-hold-from-brokerages.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.